Carl Zeiss Meditec AG AFX

ZEISS Medical Technology, one of the world's leading medical technology companies, announced expansive developments across its comprehensive ZEISS Retina Workflow at the European Society of Retina Specialists (EURETINA) congress, spanning retinal imaging, surgical visualization, digital workflow technologies and vitreoretinal surgery. The innovations further strengthen ZEISS's ability to support eye care professionals and retina specialists across the continuum of retinal care, from diagnosis an

Carl Zeiss Meditec has seen its share price fall sharply in recent years, which puts the spotlight firmly on whether the current valuation is still supported by its earnings. For anyone following the stock, the key issue now is how much of that setback is already reflected in what the market is willing to pay for each euro of profit. The share price has declined 80.6% over the past 5 years, which raises the question of how investors are now weighing the business against its earnings...

Carl Zeiss Meditec (XTRA:AFX) heads into the Berenberg and Goldman Sachs 15th German Corporate Conference on 23 September with investors watching how management frames recent share performance and underlying medical technology trends. Carl Zeiss Meditec’s share price has slipped over recent months, with a 30 day share price return of down 9.11% and a year to date share price return of down 25.49%. The 1 year total shareholder return of down 34.30% points to longer running pressure on...

ZEISS Medical Technology, one of the world's leading medical technology companies, announced the expansion of its retinal imaging portfolio with the ZEISS ALTA DUO fully automated, compact, multimodal imaging solution. Combining OCT and fundus photography within a single imaging device, the new solution broadens the ZEISS retinal imaging offering and helps address the needs of practices seeking efficient access to multimodal retinal imaging. Eye care practices operate with different clinical pri

IORT demand is rising as single-session care eases capacity constraints. Portable, AI-enabled systems, brachytherapy and turnkey services offer opportunities in underserved regions.Dublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Intraoperative Radiation Therapy - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering. The global intraoperative radiation therapy market is estimated at USD 132.93 million in 2026, up fr

| Carl Zeiss Meditec AG

ZEISS Medical Technology, one of the world's leading medical technology companies, today announced the 510k clearance from the U.S. Food and Drug Administration (FDA) for ZEISS CLINIC 3601. An all-in-one cloud and browser-based software solution, ZEISS CLINIC 360 combines diagnostic and medical data into a comprehensive patient view. By making relevant information easy to access and review, the solution helps clinicians evaluate disease progression, support treatment decisions, and improve workf

Carl Zeiss Meditec (ETR:AFX) reported lower revenue and profitability for the first nine months of fiscal 2025/2026, as foreign-exchange effects, weakness in ophthalmology consumables and the suspension of certain bifocal intraocular lens sales in China weighed on results. Order entry totaled €1.60

BILLERICA, Mass., June 30, 2026--Nirrin Technologies, a developer of analytical tools designed to transform bioprocess analytics, today announced that Hyaltech, a Carl ZEISS Meditec (CZM) company has purchased an Atlas® system to support hyaluronic acid (HA) measurement workflows and evaluate advanced analytical approaches for manufacturing environments.

A weak investment climate in the Americas contributed to declines in the German company’s intraocular lens business in the first half of its fiscal year.

Last week, you might have seen that Carl Zeiss Meditec AG ( ETR:AFX ) released its first-quarter result to the market...

Carl Zeiss Meditec (ETR:AFX) reported weaker first-half results for fiscal 2025/2026 and outlined a broad restructuring plan aimed at restoring profitability over the next three years, as management pointed to currency headwinds, soft equipment demand and pressure in China’s intraocular lens busines

If you are wondering whether Carl Zeiss Meditec is simply out of favour or actually offers value at its current price, this article is going to focus squarely on what the numbers are saying. The stock has seen a 1.7% decline over the last week, a 6.4% decline over the last month, and is down 33.0% year to date and 52.4% over the last year, with a 78.4% decline over three years and 77.8% over five years. This naturally raises questions about how the current price lines up with underlying...